Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial - Daily Monitor

Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial    Daily Monitor Ivonescimab reduced the risk of death by 34% in squamous NSCLC | ASCO 2026    Managed Healthcare Executive A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China    CNBC Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026    Business Wire New dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancer    The Independent

Original source: Google News